Platinum-Resistant Ovarian Cancer Treatment Market Sees Momentum with Next-Generation Targeted Strategies | DelveInsight

The platinum-resistant ovarian cancer market is expanding due to a growing unmet need, as many patients relapse after first-line platinum therapies, driving demand for novel second- and later-line treatments. Advances in targeted therapies and immunotherapies are broadening treatment options and attracting investment. The launch of emerging therapies such as Corcept Therapeutics (relacorilant), Advenchen Laboratories (catequentinib), Regeneron Pharmaceuticals (ubamatamab), and others will further fuel the market.

LAS VEGAS, Oct. 9, 2025 /PRNewswire/ -- DelveInsight's Platinum-Resistant Ovarian Cancer Market Insights report includes a comprehensive understanding of current treatment practices, platinum-resistant ovarian cancer emerging drugs, market share of individual therapies, and current and forecasted market size from 2020 to 2034, segmented into leading markets (the US, EU4, UK, and Japan).

Platinum-Resistant Ovarian Cancer Market Summary

• The market size for platinum-resistant ovarian cancer in the leading markets is expected to grow significantly by 2034.
• The United States accounted for the highest platinum-resistant ovarian cancer treatment market size in 7MM in 2024, in comparison to the other major markets, i.e., EU4 countries, the United Kingdom, and Japan.
• Throughout the 7MM, the US accounted for the maximum cases of ovarian cancer, with around 20,000.
• Leading platinum-resistant ovarian cancer companies developing emerging therapies, such as Corcept Therapeutics, Advenchen Laboratories, Regeneron Pharmaceuticals, Laekna Therapeutics, and others, are developing new therapy for platinum-resistant ovarian cancer that can be available in the platinum-resistant ovarian cancer market in the coming years. 
• The promising platinum-resistant ovarian cancer therapies in clinical trials include Relacorilant (CORT125134), Catequentinib (Anlotinib), Ubamatamab (REGN4018) ± Cemiplimab, Afuresertib (LAE002) + Paclitaxel, and others.

Discover the platinum-resistant ovarian cancer new treatment @ New Treatments for Platinum-Resistant Ovarian Cancer

Key Factors Driving the Growth of the Platinum-Resistant Ovarian Cancer Market 

Rising Ovarian Cancer Incidence

In 2024, in the 7MM, there were around 61K incident cases of ovarian cancer. Ovarian cancer cases are increasing, and long-term projections show substantial growth in incidence and mortality, a larger patient pool increases demand for second- and later-line therapies, including treatments for platinum-resistant disease.

Validation of FRα

The validation of FRα as a predictive biomarker for ELAHERE (mirvetuximab soravtansine) marks a shift toward targeted, biomarker-driven therapies. As the only ADC evaluated in a pivotal PROC trial, mirvetuximab leverages FRα overexpression in ovarian tumors to deliver cytotoxic payloads selectively, offering a promising therapeutic strategy with improved precision and reduced off-target effects.

Emergence of Novel PROC Therapies

The treatment pipeline for PROC is expanding, with companies such as Corcept Therapeutics (relacorilant), Advenchen Laboratories (catequentinib), Regeneron Pharmaceuticals (ubamatamab), Laekna Therapeutics (afuresertib), and several others advancing candidates in clinical development.

Platinum-Resistant Ovarian Cancer Market Analysis

The treatment landscape for platinum-resistant ovarian cancer remains highly challenging, with limited responses to standard single-agent chemotherapy prompting a strong focus on targeted and combination approaches. While established therapies such as PARP inhibitors and anti-angiogenic drugs continue to serve as key options, the current momentum lies in biomarker-driven strategies and innovative mechanisms of action. A significant milestone was achieved in 2024 with the full FDA approval of ELAHERE for folate receptor alpha (FRα)-positive PROC, which delivered both progression-free and overall survival advantages compared to chemotherapy and underscored the value of molecular diagnostics in guiding therapy. At the same time, emerging agents such as relacorilant (CORT125134), combined with nab-paclitaxel, have shown notable clinical activity, and catequentinib (anlotinib), a broad-spectrum tyrosine kinase inhibitor, is being investigated for the treatment of resistant disease. Additionally, immunotherapy-based approaches, including ubamatamab (REGN4018), a MUC16-targeted bispecific T-cell engager with or without cemiplimab, and the AKT inhibitor afuresertib (LAE002) in combination with paclitaxel, highlight the field's shift toward biomarker-guided, multi-pathway treatment strategies.

To know more about platinum-resistant ovarian cancer treatment options, visit @ Approved Platinum-Resistant Ovarian Cancer Drugs

Platinum-Resistant Ovarian Cancer Competitive Landscape

The pipeline for PROC is growing, with Corcept Therapeutics (relacorilant), Advenchen Laboratories (catequentinib), Regeneron Pharmaceuticals (ubamatamab), Laekna Therapeutics (afuresertib), and others in various stages of clinical development.

Corcept Therapeutics' Relacorilant is a selective cortisol modulator that interacts specifically with the glucocorticoid receptor (GR) without affecting other hormonal receptors. Corcept is investigating its potential use in multiple severe conditions, including ovarian, adrenal, and prostate cancers, as well as Cushing's syndrome.

Advenchen Laboratories' Anlotinib is a novel oral receptor tyrosine kinase (RTK) inhibitor that targets VEGFR-2 and -3, FGFR1-4, PDGFR-α/β, c-Kit, and Ret. Through this multi-target activity it inhibits both tumor progression and angiogenesis. The drug is currently in Phase III trials for patients with platinum-sensitive or platinum-resistant recurrent or metastatic ovarian cancer.

In February 2024, Advenchen Laboratories reported that the Japan run-in cohort of three patients in the AL3818-US-002 global Phase III PROC study completed dose-limiting toxicity (DLT) assessment within six months, and the trial has now entered the close-out phase.

The anticipated launch of these emerging therapies are poised to transform the platinum-resistant ovarian cancer market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the platinum-resistant ovarian cancer market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.

Discover more about therapy for platinum-resistant ovarian cancer @ Platinum-Resistant Ovarian Cancer Clinical Trials 

Recent Developments in the Platinum-Resistant Ovarian Cancer Market

• In July 2025, Corcept Therapeutics announced submission of a new drug application (NDA) to the US FDA for its proprietary, selective cortisol modulator, relacorilant, to treat patients with PROC.
• In April 2025, Mural Oncology announced that, following review of data from its Phase II ARTISTRY-6 trial in melanoma and previously announced results from the Phase III ARTISTRY-7 trial in PROC, the company is discontinuing all clinical development of nemvaleukin alfa and plans to immediately commence the exploration of strategic alternatives focused on maximizing shareholder value.
• In March 2025, Sutro announced the completion of a strategic portfolio review, resulting in the prioritization of its wholly owned next-generation ADC programs. While Sutro will not continue the development of luveltamab tazevibulin (luvelta; being developed for PROC) on its own, it remains open to partnership opportunities.

What is Platinum-Resistant Ovarian Cancer?

Ovarian cancer accounts for only about 3% of cancers in women but stands as the fifth leading cause of cancer-related deaths, following lung, breast, colorectal, and pancreatic cancers. It can arise from various ovarian cell types, including the epithelial cells that line the ovary, germ cells that form eggs, and stromal cells involved in hormone secretion and providing structural support. Although less common, ovarian cancer carries the highest fatality rate among gynecologic cancers and is often called a 'silent killer' because it typically progresses without apparent symptoms and lacks reliable screening tools. As a result, nearly 75% of patients are diagnosed at advanced stages. Compared to breast cancer, it is rarer but almost three times more lethal. Platinum-based chemotherapy remains the mainstay of treatment, yet relapse is common. Platinum-resistant ovarian cancer (PROC) is characterized by disease recurrence within six months of completing platinum therapy, posing a significant therapeutic hurdle due to drug resistance.

Platinum-Resistant Ovarian Cancer Epidemiology Segmentation

The platinum-resistant ovarian cancer epidemiology section provides insights into the historical and current platinum-resistant ovarian cancer patient pool and forecasted trends for the leading markets. Among type-specific cases of ovarian cancer, serous ovarian cancer accounted for the maximum number of cases throughout the 7MM. Approximately 80% of patients with advanced ovarian cancer and 20% with early-stage disease experience recurrence after first-line therapy.

The platinum-resistant ovarian cancer market report proffers epidemiological analysis for the study period 2020–2034 in the leading markets, segmented into:

• Total Incident Cases of Ovarian Cancer
• Site-specific Incident Cases of Ovarian Cancer
• Stage-specific Incident Cases of Ovarian Cancer
• Mutation-specific Incident Cases of Ovarian Cancer
• Line-wise Treated Cases of Ovarian Cancer
• Total Incident Cases of Platinum-Resistant Ovarian Cancer

Scope of the Platinum-Resistant Ovarian Cancer  Market Report

• Therapeutic Assessment: Platinum-Resistant Ovarian Cancer current marketed and emerging therapies
• Platinum-Resistant Ovarian Cancer Market Dynamics: Key Market Forecast Assumptions of Emerging Platinum-Resistant Ovarian Cancer Drugs and Market Outlook
• Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
• Unmet Needs, KOL's views, Analyst's views, Platinum-Resistant Ovarian Cancer Market Access and Reimbursement

Download the report to understand which factors are driving platinum-resistant ovarian cancer therapeutics market trends @ Platinum-Resistant Ovarian Cancer Market Trends

Table of Contents

Related Reports

Ovarian Cancer Market

Ovarian Cancer Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key ovarian cancer companies, including Verastem Oncology, Corcept Therapeutics, AstraZeneca, ProfoundBio, Genmab, Mural Oncology, Genelux Corporation, Advenchen Laboratories, Daiichi Sankyo, Sutro Biopharma, Merck, Kelun-Biotech, among others.

Ovarian Cancer Clinical Trial Analysis 

Ovarian Cancer Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key ovarian cancer companies, including Allarity Therapeutics, OSE Immunotherapeutic, Cristal Therapeutics, Bristol-Myers Squibb, Ono Pharmaceuticals, Merck & Co., Aravive Biologics, Mersana Therapeutics, Clovis Oncology, Verastem Oncology, Gradalis, AbbVie, Elevation oncology, OncoQuest Pharmaceuticals (CanariaBio), Alkermes, Hoffman-la Roche, AstraZeneca, MSD, GlaxoSmithKline, IMV, Corcept Therapeutics, among others.

Platinum-Resistant Relapsed Ovarian Cancer Market

Platinum-Resistant Relapsed Ovarian Cancer Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key platinum-resistant relapsed ovarian cancer companies, including Merck, Pfizer, AstraZeneca, ImmunoGen, Innovent Biologics, among others.

Advanced Recurrent Ovarian Cancer Market

Advanced Recurrent Ovarian Cancer Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key advanced recurrent ovarian cancer companies, including OncoQuest, Allarity Therapeutics, AstraZeneca, Jiangxi Qingfeng Pharmaceutical Co. Ltd., CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Ellipses Pharma, Merck KGaA, Pfizer, Jiangsu HengRui Medicine Co., Ltd., Puma Biotechnology, Inc., Bayer, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Daiichi Sankyo, Inc., Astellas Pharma Inc, among others.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Contact Us
Shruti Thakur
info@delveinsight.com
+14699457679
www.delveinsight.com

Logo: https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg